Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 1772-1778

  Katiyar, Santosh K ^a   Edlind, Thomas D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA GLABRATA; CONTROLLED STUDY; FKS1 GENE; FUNGAL GENE; FUSARIUM SOLANI; GENE EXPRESSION; GENE FUNCTION; GENE MAPPING; GENE MUTATION; HYBRID; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; WILD TYPE;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; FUSARIUM; GLUCOSYLTRANSFERASES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; RECOMBINATION, GENETIC; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SCEDOSPORIUM; SEQUENCE ANALYSIS, DNA;

EID: 66149144294     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00020-09     Document Type: Article

References (41)

1. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063. (Pubitemid 43807526)
2. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
3. Cornely, O. A. 2008. Aspergillus to zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36:296-313.
4. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921. (Pubitemid 43327795)
5. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
6. Desnos-Ollivier, M., S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, E. Dannaoui, et al. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
7. Douglas, C. M. 2001. Fungal β(1,3)-D-glucan synthesis. Med. Mycol. 39(Suppl. 1):55-66.
8. Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nielsen, A. M. Dahl, P. Mazur, W. Baginsky, W. Li, M. el-Sherbeini, J. A. Clemas, S. M. Mandala, B. R. Frommer, and M. B. Kurtz. 1994. The Saccharomyces cerevisiase FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc. Natl. Acad. Sci. USA 91:12907-12911.
9. Edlind, T. D., K. W. Henry, J.-P. Vermitsky, M. P. Edlind, S. Raj, and S. K. Katiyar. 2005. Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast. Curr. Genet. 48:117-125. (Pubitemid 41554567)
10. Forrest, G. N., E. Weekes, and J. K. Johnson. 2008. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 56:126-129.
11. Fréalle, E., C. Noël, N. Nolard, F. Symoens, M. S. Felipe, E. Dei-Cas, D. Camus, E. Viscogliosi, and I. Delhaes. 2006. Manganese superoxide dismutase based phylogeny of pathogenic fungi. Mol. Phylogenet. Evol. 41:28-39. (Pubitemid 44322052)
12. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
13. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
14. Ha, Y. S., S. F. Covert, and M. Momany. 2006. FsFKS1, the 1,3-β-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryot. Cell 5:1036-1042. (Pubitemid 44100702)
15. Ibrahim, A. S., J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards, Jr., and C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.
16. Imhof, A., S. A. Balajee, and K. A. Marr. 2003. New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J. Clin. Microbiol. 41:5683-5688.
17. Jain, P., I. Akula, and T. Edlind. 2003. The cyclic AMP signalling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 47:3195-3201.
18. Kahn, J. N., G. Garcia-Effron, M. J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
19. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
20. Kaufman, C. A., and P. L. Carver. 2008. Update on echinocandin antifungals. Sem. Resp. Crit. Care Med. 29:211-218.
21. Kontoyiannis, D. P., and R. E. Lewis. 2002. Antifungal drug resistance of pathogenic fungi. Lancet 359:1135-1144. (Pubitemid 34270742)
22. Kontoyiannis, D. P., M. S. Lionakis, R. E. Lewis, G. Chamilos, M. Healy, C. Perego, A. Safdar, H. Kantarjian, R. Champlin, T. J. Walsh, and I. I. Raad. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191:1350-1360.
23. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
24. Kurtz, M. B., and J. H. Rex. 2001. Glucan synthase inhibitors as antifungal agents. Adv. Protein Chem. 56:423-475. (Pubitemid 32367464)
25. Lamaris, G. A., R. E. Lewis, G. Chamilos, G. S. May, A. Safdar, T. J. Walsh, I. I. Raad, and D. P. Kontoyiannis. 2008. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186-192.
26. Laverdière, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
27. Malani, A. N., and C. A. Kauffman. 2007. Changing epidemiology of rare mould infections: implications for therapy. Drugs 67:1803-1812. (Pubitemid 47347394)
28. Maligie, M. A., and C. P. Selitrennikoff. 2005. Cryptococcus neoformans resistance to echinocandins: (1,3)β-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother. 49:2851-2856.
29. Martínez-Rocha, A. L., M. I. Roncero, A. López-Ramirez, M. Mariné, J. Guarro, G. Martínez-Cadena, and A. Di Pietro. 2008. Rho1 has distinct functions in morphogenesis, cell wall biosynthesis and virulence of Fusarium oxysporum. Cell. Microbiol. 10:1339-1351.
30. Matsue, K., H. Uryu, M. Koseki, N. Asada, and M. Takeuchi. 2006. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis. 42:753-757. (Pubitemid 43363927)
31. Mazur, P., N. Morin, W. Baginsky, M. el-Sherbeini, J. A. Clemas, J. B. Nielson, and F. Foor. 1995. Differential expression and function of two homologous subunits of yeast 1,3-β-glucan synthase. Mol. Cell. Biol. 15:5671-5681.
32. Nucci, M., and K. A. Marr. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521-526. (Pubitemid 41099648)
33. Ohyama, T., S. Miyakoshi, and F. Isono. 2004. FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-β-glucan synthase inhibitor arborcandin C. Antimicrob. Agents Chemother. 48:319-322.
34. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273. (Pubitemid 41060570)
35. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. (Pubitemid 47031054)
36. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
37. Richardson, M., and C. Lass-Flörl. 2008. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. 14(Suppl. 4):5-24.
38. Rocha, E. M. F., G. Garcia-Effron, S. Park, and D. S. Perlin. 2007. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51:4174-4176.
39. Thompson, J. R., C. M. Douglas, W. Li, C. K. Jue, B. Pramanik, X. Yuan, T. H. Rude, D. L. Toffaletti, J. R. Perfect, and M. Kurtz. 1999. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181:444-453.
40. Thompson, G. R., N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis, and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
41. Wheeler, R. T., D. Kombe, S. D. Agarwala, and G. R. Fink. 2008. Dynamic, morphotype-specific Candida albicans β-glucan exposure during infection and drug treatment. PLoS Pathog. 4:1-12.